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not been well studied, we sought to determine the efficacy and safety of these two
approaches in the management of patients with symptomatic pericardial effusion (PE).
Methods: We conducted a retrospective chart review of 193 consecutive patients who
underwent percutaneous pericardiocentesis or surgical pericardial drainage between
2007 and 2009 at our institution. In addition to baseline demographics, intra-procedural
and immediate post-procedural mechanical, cardiovascular and pulmonary
complications were assessed for each patient. Recurrence was defined as
reaccumulation of pericardial fluid requiring repeat drainage within a 3-month period.
Results: Between 2007 and 2009, 121 (62.9%) patients underwent pericardiocentesis
and 72 (37.3%) had surgical drainage for symptomatic PE. There was no significant
difference between the groups in age, sex, BMI, history of cancer,chronic kidney
disease, or prior myocardial infarction.The etiology of the effusions included post-
cardiac surgery (32.1%), malignant (17.1%), idiopathic (16.6%), iatrogenic (11.4%),
inflammatory (5.2%), and uremic (3.1%). In the pericardiocentesis group, 35 of 121
patients (28.9%) required repeat procedures compared to 2/72 (2.8%) patients in the
surgical group (OR 14.2, 95% CI [3.3-61.3], p<.0001). Nineteen patients (19/72,
26.4%) in the surgical group had a procedural complication compared to 6 patients
(6/121, 4.9%) in the pericardiocentesis group (OR 6.9, CI[ 2.6-18.2 ], p<0.0001).
Conclusion: In a single center series of symptomatic pericardial effusions, compared
to open surgical drainage, percutaneous pericardiocentesis is associated with a higher
rate of effusion recurrence requiring repeat drainage, but a lower rate of procedural
complications. Future studies will compare the long-term outcomes of
pericardiocentesis versus surgical drainage for pericardial effusion.
TCT-724
Percutaneous Closure of Multiple Paravalvular Leaks with Amplatzer Vascular
Plug III Device. Single - Center Experience
Jaime Rolando Dutary, Manuel Paulo, Rosana Hernandez, Carlos Almeria, Ana
Cuadrado, Eulogio Garcia
Interventional Cardiology, Hospital Clinico San Carlos, Madrid, Spain
Background: Multiple paravalvular leaks (MPL) are associated with increased rate
of hemolysis and congestive heart failure (CHF) compared with single and small leaks.
Methods: We describe the result of consecutive patients (P) with MPL, treated with
Amplatzer Vascular Plug III (AVP III) from December 2008 to December 2010. The
indication for paravalvular leaks transcatheter closure was: congestive heart failure
(CHF), hemolysis or both. Each patient was reviewed by at least three physicians, at
least one of which was a surgeon, regarding the risk of reoperation.
Results: A total of 22 P, were included. Of the total population 64% were male. The
mean age was 65 +/- 11 years. Fourteen P (64%) had pulmonary hypertension with a
mean pulmonary artery pressure of 65 +/- 32 mmHg and 82% were in NYHA
functional class III - IV. The mean logistic Euroscore was 18 +/- 17. The most common
indication for intervention was CHF + hemolysis (64%), isolated CHF in 4P (18%)
and hemolysis in 4 P (18%) . The mean number of previous surgery was 2 +/-1, with
a mean number of leaks of 2.5 +/- 0.5. Sixteen P (72%) had mitral MPL, 3 P (14%)
had aortic MPL and 3 P (14%) had both mitral and aortic MPL. Eighty six percent of
the MPLs were on mechanical prostheses. Success rate of AVP III implantation in all
leaks was 86%, in fourteen of them (63%) closure was achieved in only 1 procedure.
The repair was incomplete in 2 P (9%) and unsuccessful in 1 P (4%). Residual leak <
2 was obtained in 16 P (73%) with no mayor complications. No procedure related
deaths were reported. The mean follow up was 285 +/- 227 days. Functional class was
improved in 13 P (59%). Reoperation was required in 3 P (14). There were 3 cardiac
deaths, 2 of them after surgical reoperation.
Conclusion: The closure of the MPL with AVP III is a feasible procedure with a high
success rate of device implantation and low procedural mortality rate, are technically
challenging, with acceptable clinical improvement.
TCT-725
Interventional Perspective of Tricuspid Regurgitation: Heterotopic
Percutaneous Valve Implantation From Preclinical Trials to First-in-Man
Application
Alexander Lauten, Markus Ferrari, Hans R Figulla
University Heart Center Jena, Jena, Germany
Background: Heterotopic valve implantation into the caval veins has been suggested
to treat venous congestion in severe tricuspid regurgitation (TR). We report our
experience with this approach from basic preclinical studies to first human treatment.
Methods: Proof-of-concept studies were performed in a TR-sheep model. Following
the induction of TR, two valves were implanted into the superior and inferior caval
(IVC) vein resulting in a significant decrease of the ventricular wave(ν-wave) from
16.2±2.33 to 13.9±2.97mmHg and a significant rise of cardiac output from 2.9±1.16
to 4.20±0.84l/min. Valve function was documented after 6 month follow-up. Device
position and function were verified at autopsy.
Results: Based on these promising results, the first-in-man concept application was
performed for compassionate treatment in an inoperable 79-year-old patient (3 previous
heart surgeries, EuroScore 30%). In this patient, a self-expanding pericardial tissue
valve was implanted in a transcatheter approach in the IVC and anchored at the cavo-
atrial junction just above the hepatic vein inflow. After deployment, excellent device
function and valvular competence were confirmed with full systolic closure and
diastolic opening. Hemodynamics confirmed a nearly abolished ν-wave in the IVC
from 29/19 to 19/12mmHg and a decrease of mean pressure from 19 to 16mmHg.
Valve function remained excellent during the first 8 weeks of follow-up. The patient
experienced improved physical capacity and was able to resume off-bed acitivities.
There was no recurrence of RV failure and a partial reduction of ascites. She was
discharged from hospital into a rehabilitation program.
Conclusion: Transcatheter caval valve implantation is feasible and results in an
immediate abolition of IVC regurgitation in severe TR with midterm clinical
improvement. Thus, in selected non-surgical patients with TR this concept may become
an option to treat venous regurgitation and improve hepatic congestion. Further
experience with longer follow-up is required to evaluate the long-term clinical benefit.
TCT-726
Transcatheter Laser Irradiation in the Treatment of Migraine
Ivan V. Maksimovich
Clinic of Cardiovascular Diseases named after Most Holy John Tobolsky, Moscow,
Russian Federation
Background: One of the causes of migraine is arterial insufficiency of the brain that
is most often caused by vascular hypoplasia, a congenital systemic lesion.
Methods: 42 patients aged 30-57 (average age 41) suffering from severe migraine and
vestibular disorders, and having long been under ineffective conservative therapy, were
examined and operated on. In all cases the investigation plan included CT, MRI, SG,
REG, and MUGA. Patient selection criteria were the absence of pronounced
atherosclerotic lesions of intracranial branches and the presence of hypoplasia (anterior
cerebral artery trunk diameter less than 0.9 mm, middle cerebral artery trunk diameter
less than 2.4 mm.). CT and MRI revealed: enlargement of the subarachnoid space in
12 (28.57%) cases, blurred relief of convexital surface of the hemispheres in 11
(26.19%) cases, blurred boundaries of gray and white matter of the brain in 40
(95.23%) cases, hydrocephalus phenomenon in 31 (73.80%) cases. According to
MUGA, all 42 patients did not have any pronounced atherosclerotic lesions of
intracranial branches, 8 (19.04%) patients had hemodynamically insignificant stenosis
of extracranial vessels. For transcatheter laser irradiation low-energy laser systems
were used.
Results: Immediate angiographic outcome, i.e. persistent expansion of intracranial
blood vessels back to the norm after transcatheter laser irradiation, was obtained in 40
(95.24%) cases. Good clinical outcome, i.e. almost complete disappearance of migraine
and vestibular disorders, was obtained in 37 (88.09%) cases. Satisfactory clinical
outcome, i.e. incomplete disappearance of migraine and vestibular disorders, was
observed in 5 (11.90%) cases. 6-12 months after the laser treatment CT and MRI
revealed improved visualization of brain structures in 38 (90.48%) cases, reduction of
hydrocephalus phenomena in 28 (90.32%) cases. Improved cerebral blood flow was
observed in 41 (97.62%) cases.
Conclusion: The results obtained show high efficiency of the method of transcatheter
laser irradiation in the treatment of migraine accompanied by brain vessels hypoplasia.
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Most Patients Fulfil The Access Way Criteria In Transcatheter Aortic Valve
Implantation
Daniel John1, Jutta Kulow1, Seyrani Yücel2, Ulrich Gerckens2, Eberhard Grube3,
Christoph K. Naber1, Oliver Bruder1
1Elisabeth Hospital, Department of Cardiology & Angiology, Essen, Germany; 2St.
Petrus Hospital, Department of Cardiology, Bonn, Germany; 3Universitätsklinikum
Bonn, II. Medizinische Klinik, Bonn, Germany
Background: Transcatheter aortic valve implantation (TAVI) is a rapidly evolving
technique for high-risk patients with significant aortic stenosis (AS). Using the
Medtronic CoreValve Prosthesis (MCV) the trans-femoral (TF) access is widely
accepted to be the first choice whereas the left subclavian artery (SA) is used as an
alternative AW. Contrast-enhanced multi-slice computed tomography (MSCT) is
established for non-invasive evaluation of AW in TAVI. It is not known, how many
patients with AS fail the anatomical criteria and therefore are not treatable using TAVI
with the MCV. Aim of the study was to identify the proportion of TAVI patients not
eligible using these widely used AW.
Methods: We retrospectively analyzed 533 patients with severe AS (81.08+/-6.32
years, 248 men) scheduled for TAVI between 07/2008 and 10/2010. In all patients, a
contrast-enhanced MSCT was performed. The femoral AW were evaluated in all
patients. TF AW was classified as possible, if 3 conditions were fulfilled: diameter >
6 mm, maximal moderate calcification and angulation. Patients were classified as
treatable if one side was acceptable. In the remaining patients, evaluation of the SA
was performed. The trans-subclavian AW was accepted, when the following conditions
were present: diameter > 6 mm, low calcification and maximal moderate angulation
till the level of the upper thoracic outlet.
Results: Using the right TF AW, patients were formally treatable in 55.9% compared
to 47.5% using the left TF AW. Taking both sides into account, the number of patients
B193JACC Vol 58/20/Suppl B  |  November 7-11, 2011  |  TCT Abstracts/POSTER/Valvular Heart Disease - Aortic
P
O
S
T
E
R
S
www.JACC.TCTAbstracts2011
TUESDAY, NOVEMBER 8, 2011, 8:00 AM - 10:00 AM
with possible TF approach was substantially higher (70.2%). In the remaining 29.8%
not treatable using this AW, 48.4% fulfilled the anatomical criteria regarding the SA.
In summary, 84.6% of patients provide suitable AW for “conventional” TAVI with the
MCV.
Conclusion: The majority of patients with AVS scheduled for TAVI show sufficient
AW for “conventional” TAVI with the MCV. Anyhow, a substantial number of patients
are not eligible due to inappropriate AW. Consecutively, the retrograde trans-aortic
AW, which is rarely performed, may be an option to solve this problem.
TCT-728
Sutureless Implantation of a Expandable Mitral Stent-Valve Prosthesis in Acute
Animal Model
Jose Luis Navia, Ji-Feng Chen, Shengqiang Gao, Qun Zhou, Leonardo Rodriguez,
Nicolas Brozzi, Jamshid Karimov, Kiyotaka Fukamachi
Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH
Background: Minimally-invasive and transcatheter approaches have become very
popular particularly for aortic valve procedures. While the former continues to improve
the operative technique, the application of catheter-delivery technologies in selected
high risk patients is becoming more and more challenging. This is more specifically
true for patients with mitral regurgitation who present a burgeoning clinical unmet
need for therapeutic advances and a transcatheter implanted mitral valve may offer a
very effective treatment alternative and this begins with the sutureless implantation of
such device.
Methods: This study describes the initial results of the feasibility study of the sutureless
implantation of mitral valve prostheses in an acute ovine model. The device consists
of a pericardial bioprosthetic valve mounted within a expandable support structure.
The device is collapsed radially and balloon expanded radially, thereby providing a
secure attachment to the valve annulus without requiring sutures. The new stent-valve
was designed for a prospective catheter delivered implantation technique. The stent-
valves were deployed in the mitral annular position, through a left thoracotomy access,
cardiopulmonary bypass (CPB) institution and direct valve implantation in a beating
heart.
Results: All valves were successfully implanted. Echocardiographic assessment
confirmed excellent function of the bioprosthetic mitral valve with accurate positioning
and secure anchoring of the stent-valve onto the mitral annulus. Even at the highest
registered systolic AoP (>200 mmHg) with its attendant extreme dP/dt, there was no
dislocation of any part or the valve. No perivalvular leak or central mitral regurgitation
was observed. Confirmation of a clear unobstructed LVOT with preservation of the
subvalvular apparatus. Valve function evidenced normal hemodynamic performance
and pressure gradient across the implanted valve.
Conclusion: The new design of a contractible and expandable mitral valve prosthesis
demonstrated reliable valve performance, secure engagement of the native annulus
confirms the feasibility and suggests potential ease of implantation. Further chronic
study is needed to verify these results and evaluate reliability of implantation
procedures, biocompatibility, and valve durability. This signals that transition to a
transcatheter valve delivery may be eased by the attributes of this new device.
TCT-729
Reduced incidence of bleedings, vascular complications and 30 days mortality
with the Sapien Novaflex system: Results from a single center Tansfemoral-
TAVI registry
Giovanni Sorropago, Eugenio Stabile, Armando Pucciarelli, Linda Cota, Angelo
Cioppa, Marco Agrusta, Vittorio Ambrosini, Vincenzo Lucchetti, Paolo Rubino
clinica montevergine, Mercogliano, Italy
Background: Transcatheter aortic valve implantation (TAVI) is performed via the
trans-femoral (TF) route as the first choice delivery approach with encouraging results
from worldwide registries. Vascular access management is a major challenge in TF
TAVI due to the need for large-sized introducer sheaths. Bleedings are common
complications of the TAVI procedure are related to sheath size. The new generations
of TAVI systems are significatively smaller than the first generation systems.In this
study we report the incidence of bleedings in patients undergoing TAVI in a single
centre institution.
Methods: From June 2008 to May 2011, a total of 156 patients in our institutions
underwent TAVI using the TF approach. Patients were divided into two groups
according to the TAVI system adopted: Group A (Retroflex, Edwards Life Sciences)
and Group B (Novaflex, Edwards Life Sciences). Patients received a detailed clinical
assessment and serial blood testing before and one hour, twenty four hours and at
discharge after TAVI. At one month patients underwent a clinical follow up visit.
Bleedings and vascular complications were classified according to the VARC criteria.
Results: At 30 days the incidence of mayor and minor vascular complications was
significatively lower in group B (p<0.05). No distal embolizations occurred in any of
the groups. The reduced incidence of vascular complications was associated with a
reduced incidence of Life-Threatening Bleedings, Mayor Bleedings and Minor
bleedings were significatively, in group B (p<0.05). Overall this resulted into a
significative reduction in 30 days mortality (7.7 % vs 1.6%, (p<0.05) and in particular
annealed the occurrence of vascular related.
Conclusion: The use of the Novaflex system allowed a reduction of post TAVI
bleedings, vascular complications, vascular related deaths and 30 mortality. This data,
if confirmed in a large metacentre registry, would further support the diffusion of TAVI
for the treatment of patients with severe aortic stenosis and at high surgical risk.
TCT-730
Transcranial Doppler Analysis of Embolic Events during Transcatheter Aortic
Valve Implantation
William T Brinkman1, Karen L Roper1, Rebeca Kim1, Morley A Herbert2, Stuart J
Head3, Ashley M Stone1, Todd M Dewey2, 1, Michael J Mack1
1CRSTI, Dallas, TX; 2Medical City Dallas, Dallas, TX; 3Erasmus University Medical
Center, Rotterdam, Netherlands
Background: Neurologic impairment post AVR correlates with Transcranial Doppler
(TCD)-measured embolic high intensity signals (HITS), but less is known about their
occurrence in the transcatheter-based aortic valve insertion (TAVI) procedures where
risk for stroke is reported to be higher. This study compares HITS across common
events during TF-transfemoral and TA-transapical TAVI.
Methods: Output from TCD provided time-stamped HITS detection and artifacts
rejection. Procedural events were marked throughout TAVI-TF (n=21) and TAVI-TA
(n=21). HITS during BAV- and Valve- delivery System Intervals (B-SI and V-SI) were
then compared. Balloon delivery system (TF) or apical sheath insertion (TA) marked
B-SI start. VS-I was initiated (and B-SI ended) with insertion of the valve delivery
system (into the arch for TF and into the apex for TA). VS-I ended when 60 seconds
had passed following valve delivery system removal (TF) or apical sheath removal
(TA). Specific events within each interval were also compared, with HITS counted for
60sec following each.
Results: Though not significant (p=0.1), total HITS were greater in TAVI-TF (674)
than TA (542). In both procedures, V-SI created more emboli than B-SI (p<0.001).
Subdivision of the events during VS-I revealed a larger number of HITS during valve
deployment in TF than TA (p< .01). Advancement of the valve across the aortic arch
(unique to TF) also contributed. B-SI HITS were highest during TA insertion of the
apical sheath.
Conclusion: Patients are at more risk for embolic events during valve deployment than
during BAV. TAVI procedures may benefit from an intravascular filter prior to delivery
across the aortic arch in TF and placement prior to apical sheath insertion in TA.
TCT-731
Clinical and functional outcome after transapical aortic valve implantation
using the JenaValveTM AVR System – Results of the first-in-man study after one
year
Ardawan J Rastan1, Joerg Kempfert1, Thomas Walther1, Hans R Figulla2, Markus
Ferrari2, Gerhard Schuler1, Martin Haensig1, Axel Linke1, Katrin Leadley3, Andreas
Marx3, David M Holzhey1, Friedrich W Mohr1
1Heart Center, University of Leipzig, Leipzig, Germany; 2Department of Cardiology,
University of Jena, Jena, Germany; 3JenaValve Technology GmbH, München,
Germany
Background: To evaluate the feasibility, safety and valve performance of the
JenaValveTM for transapical transcatheter aortic valve implantation (TAVI) during the
first-in-man (FIM) study.
Methods: The JenaValveTM aortic valve replacement (AVR) TAVI System is composed
of a porcine xenograft attached on a self-expandable Nitinol stent. It allows precise
anatomical valve orientation by three positioning arms. The stent design anchoring the
native leaflets, the sub-coronary position and the possibility of retrieving the valve
before final release provide potential advantages compared to current TAVI systems.
Between 07/09 and 04/2010 twelve patients were enrolled. Mean age was 85.9±4.0
years, all patients were female, log EuroSCORE was 24.7±10.5% and STS score was
10.3±4.3. Native annulus size was 21.4±1.2mm. The procedure was aborted in one
patient due to acute type A dissection and in two patients because the positioning arms
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